Stock BCYP BIG CYPR
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

BIG CYPR Stock

Equities

BCYP

US0891151096

Chart BIG CYPR

Dynamic Chart

Latest news about BIG CYPR

Big Cypress Acquisition Corp.(NasdaqCM:BCYP) dropped from NASDAQ Composite Index CI
SAB Biotherapeutics, Inc. completed the acquisition of Big Cypress Acquisition Corp. in a reverse merger transaction. CI
Big Cypress Acquisition Corp. Announces Board Changes CI
Certain Common Stock of Big Cypress Acquisition Corp. are subject to a Lock-Up Agreement Ending on 10-JUL-2021. CI
Big Cypress Acquisition : Says First Patient Dosed in SAB Biotherapeutics' Phase 2a Influenza Drug Trial MT
Big Cypress Acquisition : to Merge With SAB Biotherapeutics; Combined Firm to Go Public MT
SAB Biotherapeutics, Inc. entered into nonbinding letter of intent to acquire Big Cypress Acquisition Corp. in a reverse merger transaction for approximately $410 million. CI
Big Cypress Acquisition Corp.(NasdaqCM:BCYP) added to NASDAQ Composite Index CI
Big Cypress Acquisition Corp. announced that it has received $4.172 million in funding from Big Cypress Holdings LLC CI
Big Cypress Acquisition Corp. has completed an IPO in the amount of $100 million. CI
Big Cypress Acquisition Corp. announced that it expects to receive $3.8225 million in funding from Big Cypress Holdings LLC CI
Big Cypress Acquisition Corp. has filed an IPO in the amount of $75 million. CI
More news

Press releases BIG CYPR

UNAUDITED PRO FORMA COMBINED CONDENSED CONSOLIDATED FINANCIAL INFORMATION - Form 8-K PU
BIG CYPRESS ACQUISITION CORP. : Submission of Matters to a Vote of Security Holders (form 8-K) AQ
Big Cypress Acquisition Corp. : Stockholders Approve Business Combination with SAB Biotherapeutics PR
SAB Corporate Presentation PU
BIG CYPRESS ACQUISITION CORP. : Other Events (form 8-K) AQ
More press releases

News in other languages on BIG CYPR

SAB Biotherapeutics: SAB-185 zur Behandlung von COVID-19 erhält positive DSMB-Stellungnahme und erreicht Phase 3 in NIH-gesponserter Studie ACTIV-2
SAB Biotherapeutics : annonce que le SAB-185 a reçu une très bonne évaluation d'un comité de contrôle des données (CICD) et qu'il progresse désormais vers la Phase 3 dans le cadre de l'essai ACTIV-2 sponsorisé par les National Institutes of Health...
SAB Biotherapeutics : anuncia la revisión positiva del DSMB para SAB-185, que pasa a la fase 3 en el ensayo ACTIV-2 patrocinado por los NIH para el tratamiento de la COVID-19
More news

Company Profile

Big Cypress Acquisition Corp is a blank check company. The Company is formed for the purpose of effecting an initial business combination with one or more target businesses. The Company have not selected any specific target business. The Company may pursue an acquisition opportunity in any industry or sector, and intends to acquire and manage a business in the life sciences industry.
Sector
-
More about the company
  1. Stock Market
  2. Equities
  3. BCYP Stock